Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIANCE: Ranibizumab vs Conbercept in nAMD
NCT02577107Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2016
- Primary completion
- Jul 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Day 8. Started Jan 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02577107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577107.